Brief: CEL-SCI Provides Phase 3 Population Analysis Results For Multikine

CEL-SCI

26/07/2024 13:29

July 26 (Reuters) - CEL-SCI Corp  CVM.A :
    * CEL-SCI’S PHASE 3 POPULATION ANALYSIS FOR UPCOMING
CONFIRMATORY
REGISTRATION STUDY IN HEAD & NECK CANCER DEMONSTRATES WELL
BALANCED PATIENT POPULATION, CONFIDENCE IN CLINICAL RESULTS
    * CEL-SCI CORP - STUDY DATA ARE RELIABLY INTERPRETABLE,
STATISTICALLY SIGNIFICANT
    * CEL-SCI - DATA SUPPORTS CLINICAL EFFECT OF NEOADJUVANT
(PRE-SURGERY) MULTIKINE IMMUNOTHERAPY IN EXTENDING LIFE OF
PATIENTS IN PHASE 3 STUDY

Source text for Eikon:  ID:nBw4TDtKGa 
Further company coverage:  CVM.A 

 ((Reuters.Briefs@thomsonreuters.com;))